As indicated by Picke et al., bone defect regeneration may be affected by typical T2DM molecular imbalances [13], which are reverted by insulin treatment but not by the anabolic treatments anti-sclerostin and PTH. This evidence concerns the gene PTH and type 2 diabetes mellitus.